Fulgent Genetics, Inc.
Company Stats
- Market Cap
- $605.9M
- as of Sep 30, 2026
- Shares Outstanding
- 27.5M
- Free Float
- 22.9%
Income Statement
- Revenue
- $322.7M
- Operating Income
- -$91.1M
- Net Income
- -$60.5M
- EBITDA
- -$67.0M
- Non-cash Impairment
- $9.9M
- Revenue Growth, 3Y
- -19.5%
- FCF Margin, 3Y Avg
- -14.5%
- FCF Margin, Worst Year
- -38.5%
Cash Flow
- Free Cash Flow
- -$124.2M
- FCF Yield
- -20.5%
- Owner FCF Yield
- -27.0%
Balance Sheet
- Cash & Equivalents
- $50.2M
Returns & Capital
- Share Repurchases
- $10.9M
- Buyback Yield, 3Y Avg
- 2.0%
- SBC, 3Y Avg
- $42.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $322.7M | -$124.2M | -38.5% |
| FY2024 | $283.5M | -$19.3M | -6.8% |
| FY2023 | $289.2M | $4.8M | 1.7% |
| FY2022 | $619.0M | $234.7M | 37.9% |
| FY2021 | $992.6M | $514.8M | 51.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back